S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The Ultimate Passive Income Play (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
The Ultimate Passive Income Play (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The Ultimate Passive Income Play (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
The Ultimate Passive Income Play (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The Ultimate Passive Income Play (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
The Ultimate Passive Income Play (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
The Ultimate Passive Income Play (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
The Ultimate Passive Income Play (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Recession risks are fading, business economists say, but political tensions pose threat to economy
The Ultimate Passive Income Play (Ad)
Stock market today: World shares mostly higher after S&P 500 tops 5,000
Biden's campaign joins TikTok, even as administration warns of national security concerns with app
NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

$137.84
-5.49 (-3.83%)
(As of 02/9/2024 08:56 PM ET)
Compare
Today's Range
$135.30
▼
$147.70
50-Day Range
$111.76
▼
$147.20
52-Week Range
$89.00
▼
$238.55
Volume
3.73 million shs
Average Volume
1.95 million shs
Market Capitalization
$21.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$166.95
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.32 Rating Score
Upside/​Downside
21.1% Upside
$166.95 Price Target
Short Interest
Healthy
2.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.43mentions of Illumina in the last 14 days
Based on 36 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
121.36%
From $1.03 to $2.28 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

103rd out of 922 stocks

Analytical Instruments Industry

5th out of 28 stocks

See Top Rated MarketRank™ Stocks Here

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

January 22, 2024 | marketbeat.com
MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs (ILMN)
With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs.
February 11, 2024 | americanbankingnews.com
Royal Bank of Canada Reaffirms "Outperform" Rating for Illumina (NASDAQ:ILMN)
February 12, 2024 | Stansberry Research (Ad)
Billionaires Are Now FLOODING Into Gold
Ray Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5).
February 10, 2024 | americanbankingnews.com
Analysts Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $170.90
February 9, 2024 | msn.com
Analyst reaction mixed to Illumina 2024 forecast
February 9, 2024 | markets.businessinsider.com
Illumina Sell Rating: Competitive Pressures and Uncertain Margins Dim Prospects
February 9, 2024 | msn.com
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
February 9, 2024 | realmoney.thestreet.com
Illumina price target raised by $5 at BofA, here's why
February 12, 2024 | Porter and Company (Ad)
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI"
If this tech goes mainstream, it could destroy the oil and gas industry, the clean energy sector, and the billionaires who profit from it…
February 9, 2024 | markets.businessinsider.com
Illumina Inc.: Steady Performance with Cautious Outlook Justifies Hold Rating
February 9, 2024 | msn.com
DNA Sequencing Kit Provider Illumina's Q4 Earnings Edge Above Street Estimates, Works To Resolve GRAIL Quickly
February 9, 2024 | finance.yahoo.com
Illumina, Inc. (NASDAQ:ILMN) Q4 2023 Earnings Call Transcript
February 9, 2024 | markets.businessinsider.com
Illumina: Hold Recommendation with Increased Price Target Amidst Growth and Market Challenges
February 9, 2024 | finance.yahoo.com
Q4 2023 Illumina Inc Earnings Call
February 9, 2024 | americanbankingnews.com
Illumina (NASDAQ:ILMN) Stock Rating Upgraded by StockNews.com
February 8, 2024 | marketwatch.com
Illumina 4Q Revenue Higher Amid Grail Divestiture
February 8, 2024 | msn.com
Illumina beats top-line and bottom-line estimates; initiates FY24 outlook
February 8, 2024 | chron.com
Illumina: Q4 Earnings Snapshot
February 8, 2024 | markets.businessinsider.com
Illumina Inc. Q4 Earnings Summary
February 8, 2024 | finance.yahoo.com
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
February 8, 2024 | finance.yahoo.com
Illumina Inc (ILMN) Reports Mixed Fiscal Year 2023 Results Amidst GRAIL Divestiture
February 8, 2024 | finance.yahoo.com
Illumina forecasts flat 2024 sales as sluggish demand drags on
February 8, 2024 | finance.yahoo.com
Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say
February 8, 2024 | msn.com
Options Volatility and Implied Earnings Moves Today, February 08, 2024
February 7, 2024 | finance.yahoo.com
HRMY or ILMN: Which Is the Better Value Stock Right Now?
February 7, 2024 | americanbankingnews.com
Illumina (ILMN) Set to Announce Quarterly Earnings on Thursday
February 5, 2024 | finance.yahoo.com
Seeking Clues to Illumina (ILMN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/12/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
CIK
1110803
Web
www.illumina.com
Phone
(858) 202-4500
Fax
858-202-4766
Employees
10,260
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$166.95
High Stock Price Target
$258.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+21.1%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
19 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($7.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
133.83
P/E Growth
24.83
Net Income
$-4,404,000,000.00
Net Margins
-25.78%
Pretax Margin
-24.99%
Return on Equity
2.15%
Return on Assets
1.22%

Debt

Debt-to-Equity Ratio
0.25
Current Ratio
1.69
Quick Ratio
1.28

Sales & Book Value

Annual Sales
$4.50 billion
Price / Sales
4.86
Cash Flow
$4.64 per share
Price / Cash Flow
29.70
Book Value
$41.95 per share
Price / Book
3.29

Miscellaneous

Outstanding Shares
158,800,000
Free Float
158,594,000
Market Cap
$21.89 billion
Optionable
Optionable
Beta
1.22

Social Links

A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for February 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., CFO, Chief Strategy & Corporate Development Officer
    Comp: $787.3k
  • Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
  • Stephanie Campos
    President
  • Mr. Kevin Carl Pegels (Age 57)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 52)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 54)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.06M
  • Ms. Kathryne Gambrell Reeves (Age 55)
    Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Illumina was last updated on Sunday, February 4, 2024 at 7:30 PM.

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. This positions the company in a growing industry with high demand for genetic research and analysis.
  • The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation. These products are essential for genetic sequencing and analysis, making Illumina a key player in the market.
  • Illumina provides whole-genome sequencing kits, which sequence entire genomes of any size and complexity. This technology allows for comprehensive genetic analysis and has wide applications in research and healthcare.
  • The company serves a diverse customer base, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics companies. This broad customer base provides a stable and diversified revenue stream.
  • Illumina has a global presence, with direct sales to customers in North America, Europe, Latin America, and the Asia-Pacific region. It also sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. This global reach allows the company to tap into different markets and expand its customer base.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • The stock price of Illumina, Inc. is subject to market fluctuations and can be influenced by various factors such as economic conditions, industry trends, and company performance. Investors should carefully consider the risks associated with investing in the stock market.
  • The life sciences industry is highly competitive, with numerous companies offering similar products and services. Illumina faces competition from both established players and emerging companies, which could impact its market share and profitability.
  • Regulatory and legal challenges can pose risks to Illumina's operations. The company operates in a highly regulated industry and is subject to various laws and regulations related to genetic research, data privacy, and healthcare. Changes in regulations or legal disputes could have a negative impact on the company's business.
  • Investing in Illumina, Inc. involves risks associated with technological advancements and innovation. The life sciences industry is constantly evolving, and new technologies and products could disrupt the market or render existing products obsolete. Investors should consider the potential impact of technological advancements on Illumina's business.
  • Fluctuations in currency exchange rates can affect Illumina's financial performance, especially since the company operates globally. Changes in exchange rates can impact the company's revenue, expenses, and profitability.














ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

What is Illumina's stock price target for 2024?

19 equities research analysts have issued 12-month price targets for Illumina's stock. Their ILMN share price targets range from $80.00 to $258.00. On average, they expect the company's stock price to reach $166.95 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 on January 1st, 2024. Since then, ILMN shares have decreased by 1.0% and is now trading at $137.84.
View the best growth stocks for 2024 here.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our ILMN earnings forecast.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings data on Thursday, February, 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. The life sciences company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive trailing twelve-month return on equity of 2.15% and a negative net margin of 25.78%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the company earned $0.14 earnings per share.
Read the conference call transcript.

What ETFs hold Illumina's stock?

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and Global X Genomics & Biotechnology ETF (GNOM).

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.32%), GUARDCAP ASSET MANAGEMENT Ltd (1.29%), Norges Bank (1.20%), Charles Schwab Investment Management Inc. (0.58%), Ownership Capital B.V. (0.51%) and Nuance Investments LLC (0.45%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 2/12/2024 by MarketBeat.com Staff

My Account -